News
KIST Selects Its Second KIST Fellow Researcher (November 1, 2022)
- Date : 2022-11-01
- Views : 826
-
Writer
International Cooperation Team
-
Att.
KIST Selects Its Second KIST Fellow Researcher
The Korea Institute of Science and Technology (KIST; President: Seok-Jin Yoon) announced on November 1 that it had selected Dr. In-San Kim (Chemical & Biological Integrative Research Center) as the second KIST Fellow Researcher. KIST Fellow Researchers are researchers who have made outstanding achievements and are recognized and respected at the institutional level.
The purpose of the KIST Fellowship, established in April 2021, is to promote pride among researchers and support their ongoing research activities by providing institutional recognition and courtesy to those who have achieved excellent research achievements and achievements. Last year, Dr. Heon Phil Ha as a KIST Fellow, and in September of this year, KIST announced the selection of the second KIST Fellow and began accepting letters of recommendation for candidates. In the end, Dr. In-San Kim was selected as the second KIST Fellow by a peer review of overseas scholars and the KIST Fellowship Committee, which is composed entirely of external experts.
Dr. In-San Kim is a doctor majoring in medicine and bioscientist majoring in biochemistry and molecular biology, and has been appraised as a representative scholar in convergence medicine research, which is rare in Korea. In particular, he has been recognized as a global leader in this field, owing to his world-class achievements in research on the development of ferritin treatments and exosome-based treatments, which are nanomaterials derived from the human body that have been gaining worldwide attention. Dr. Kim founded SHIFTBIO, a company specializing in developing new exosome-based drugs, oversaw the transfer of the technology to LabGenomics, a domestic listed company, and continued to contribute to the academic development of the field by publishing papers in highly-cited journals. Based on these achievements, he received the first Lim Seong-ki Researcher Award in 2021 and the Order of Science and Technology Merit Hyeoksin (Reformation) Medal in 2022.
Dr. Kim's main research field, exosome-based new drug technologies, has high potential for future development at a time when the demand for research into treatments for cancer and intractable diseases is expected to accelerate due to the aging population. Dr. Kim commented, "We are seeking to solve the societal problems brought on by expensive anti-cancer treatments by applying treatment technologies which are already in use."
KIST Fellows are eligible to receive 200 million won per year in research funding for up to 6 years, and may also apply for top positions at KIST. The President of KIST, Seok-Jin Yoon, stated, "Through the KIST Fellowship, which marks its second year this year, we will encourage our researchers to focus with pride exclusively on their research, while developing the Fellowship into an honorable and symbolic system throughcontinuous supplementation."